Sarah Ferber graduated at the Technion under the supervision of Prof. Hershko and Prof. Ciechanover on revealing the biology of the Ubiquitin system for protein degradation (Nobel Prize in 2004). She completed her post-Doctoral studies at Harvard Medical School and moved to Diabetes Cell Therapy in UTSW-Dallas TX. She established her own research lab at Sheba Medical Center, Israel and was the first to demonstrate liver to pancreas transdifferentiation in vivo (Nature Med 2000) and in human tissues in vitro for generating an autologous insulin producing tissue. She has since published in leading journals, and her papers were cited >2800 times. She has been serving on editorial boards of reputed journals and on the Israeli and the European boards of Gene and Cell Therapy Societies. She is the founder of Orgenesis, a cell therapy biotech company, and is the inventor of numerous patents on adult cells reprogramming.